Your browser doesn't support javascript.
loading
Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications.
Gonzales, Fanny; Barthélémy, Adeline; Peyrouze, Pauline; Fenwarth, Laurène; Preudhomme, Claude; Duployez, Nicolas; Cheok, Meyling H.
Afiliação
  • Gonzales F; Factors of Leukemic cell Persistence, Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, Canther, Lille, France.
  • Barthélémy A; Pediatric Hematology Department, University Hospital of Lille, Lille, France.
  • Peyrouze P; Factors of Leukemic cell Persistence, Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, Canther, Lille, France.
  • Fenwarth L; Factors of Leukemic cell Persistence, Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, Canther, Lille, France.
  • Preudhomme C; Factors of Leukemic cell Persistence, Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, Canther, Lille, France.
  • Duployez N; Laboratory of Hematology, CHU Lille, Lille, France.
  • Cheok MH; Factors of Leukemic cell Persistence, Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, Canther, Lille, France.
Expert Opin Ther Targets ; 25(4): 299-309, 2021 04.
Article em En | MEDLINE | ID: mdl-33906574

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Subunidade alfa 2 de Fator de Ligação ao Core / Terapia de Alvo Molecular Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Subunidade alfa 2 de Fator de Ligação ao Core / Terapia de Alvo Molecular Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article